SCI Abstract

search
+
Clinical course and management of pembrolizumab-associated isolated adrenocorticotrophic hormone deficiency: a new case and literature review
Hypophysitis is rarely reported in patients receiving pembrolizumab-only immunotherapies. Since the clinical presentation ...
Atherosclerosis: immunopathogenesis and strategies for immunotherapy
Atherosclerosis, a chronic inflammatory condition in which atheroma accumulates within the intima of the arterial wall, is...
Anti-PD-1 and regorafenib induce severe multisystem adverse events in microsatellite stability metastatic colorectal cancer: a case report
There exists a dilemma in the treatment of microsatellite stability (MSS) metastatic colorectal cancer (mCRC) owing to lim...
Durable response after immune checkpoint inhibitor-related diabetes in mismatch repair deficient pancreatic cancer
Mismatch repair protein deficiency occurs in 0.8–2% of pancreatic ductal adenocarcinomas and confers susceptibility to imm...
Real-world treatment patterns and outcomes in PD-L1-positive non-small cell lung cancer
Aim: We report real-world treatment patterns and outcomes in patients with PD-L1+ non-small cell lung cancer (NSCLC). Meth...
Patient needs and benefits of sublingual immunotherapy for grass pollen-induced allergic rhinitis: an observational study
Aim: Clinical efficacy of sublingual immunotherapy for grass pollen-induced allergic rhinitis (AR) needs to translate into...
Pretreatment lung immune prognostic index as a biomarker in advanced non-small-cell lung cancer patients receiving first line pembrolizumab
Background: To investigate the role of pretreatment lung immune prognostic index (LIPI) as biomarker in PD-L1 ≥50% non-sma...
Delayed cytokine release syndrome after neoadjuvant nivolumab: a case report and literature review
Aim: Cytokine release syndrome (CRS) is an infrequently described immune-related adverse event of checkpoint inhibitors (C...
Chemotherapy or chemo-immunotherapy as first-line treatment for extensive-stage small-cell lung cancer – a meta-analysis
This meta-analysis investigated the clinical benefits of chemo-immunotherapy in extensive-stage small-cell lung cancer (ES...
Durable complete remission of leptomeningeal melanoma by intrathecal methotrexate maintained with systemic ipilimumab
Leptomeningeal disease (LMD) is a complication of metastasized melanoma, with poor prognosis even in the era of immunother...
Enteric plexus neuropathy associated with PD-L1 blockade in a patient with small-cell lung cancer
Immune checkpoint inhibitors have revolutionized the management of patients with cancer. The increasing use of these agent...
TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases
JAKs are intracellular protein tyrosine kinases that, through activation of STATs, are responsible for signal transduction...
Volume increase of spleen in melanoma patients undergoing immune checkpoint blockade
Aim: To find out whether treatment with immune checkpoint inhibitors (ICIs) results in volume increase of the spleen. Pati...
Immune checkpoint inhibitors for brain metastases in non-small-cell lung cancer: from rationale to clinical application
Brain metastases (BM) is common in non-small-cell lung cancer (NSCLC) patients. Immune checkpoint inhibitors (ICIs) have g...
PD-L1 expression as a predictive biomarker for immune checkpoint inhibitors: between a dream and a nightmare
PD-L1 is an important predictive biomarker for treatment by immune checkpoint inhibitors (ICIs). ICIs are now indicated fo...
Pretreatment lung immune prognostic index as biomarker in advanced non-small-cell lung cancer patients receiving first line pembrolizumab
Background: To investigate the role of pretreatment lung immune prognostic index (LIPI) as biomarker in PD-L1 ≥50% non-sma...
Immunotherapy for cholangiocarcinoma: a 2021 update
Cholangiocarcinoma (CCA) is a rare malignancy with generally dismal prognosis. Immunotherapy has revolutionized the manage...
Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models
Aim: Graft-versus-host disease (GvHD) is a major complication arising in patients undergoing allogenic hematopoietic stem ...
Checkpoint inhibitors in BCG-unresponsive nonmuscle invasive bladder cancer: can they help spare the bladder?
Intravesical BCG therapy has been for years, the standard of care in nonmuscle-invasive bladder cancer. But upon recurrenc...
Urothelial carcinoma in the era of immune checkpoint inhibitors
Bladder cancer is the seventh most frequent cancer worldwide. The majority of patients present with nonmuscle invasive dis...
Abscopal effect and resistance reversion in nivolumab-treated non-small-cell lung cancer undergoing palliative radiotherapy: a case report
Abscopal effect has been mentioned for a long time, but only recently a deeper knowledge about underlying mechanisms suppo...
CT-P13 subcutaneous infliximab in gastroenterology and rheumatology
The drug infliximab has been a key milestone in the treatment of inflammatory conditions such as Crohn's disease, ulcerati...
Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma
The use of immune checkpoint inhibitors in patients with metastatic melanoma generates clinical benefit, including improve...
Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma
SMARCA4-deficient thoracic sarcoma (DTS) is a recently noted progressive thoracic malignancy. We recently experienced thre...
Real-world study of PD-L1 testing patterns and treatment distribution in patients with metastatic non-small-cell lung cancer in Israel
Aim: We describe PD-L1 testing patterns and first-line treatment for patients with metastatic non-small-cell lung cancer i...
Real-world effectiveness of pembrolizumab in advanced melanoma: analysis of a French national clinicobiological database
Aim: To describe real-world pembrolizumab administration and outcomes for advanced melanoma in France. Materials & met...
Is there a role for immune checkpoint inhibitors in chordoma?
The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest...
Chimeric antigen receptor macrophage for glioblastoma immunotherapy: the way forward
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial intere...
Adverse events of the second-line treatment for patients with locally advanced or metastatic urothelial carcinoma of the bladder: network meta-analysis
Aim: We aimed to compare the mortality rates related to adverse events (AEs) and discontinuation of treatment due to toxic...
Current landscape of immunotherapy trials in locally advanced and high-risk head and neck cancer
The current standard of therapy for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) is limited by toxi...
Load More
format_indent_increase